Loading clinical trials...
Loading clinical trials...
A Prospective Cohort Study to Define Infectious Burden, the Seroprevalence of Vaccine Preventable Pathogens and Immune Recovery in the First Year Following Completion of Therapy in Patients With Acute Lymphoblastic Leukemia (ALL)
This observational study aims to assess recovery of the immune system and immunity to vaccine-preventable diseases in children, adolescents, and young adults who recently completed treatment for acute lymphoblastic leukemia (ALL). Several children's hospitals in the United States are participating in the study, which will enroll up to 100 pediatric participants. The study is intended to determine the rate of infection after leukemia treatment and to inform future studies and recommendations about whether children and adolescents who have leukemia should receive additional vaccine doses or boosters after treatment.
Age
3 - 31 years
Sex
ALL
Healthy Volunteers
No
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States
Helen DeVos Children's Hospital
Grand Rapids, Michigan, United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Monroe Carell Jr. Children's Hospital at Vanderbilt
Nashville, Tennessee, United States
CHRISTUS Children's (Affiliate of Baylor College of Medicine)
San Antonio, Texas, United States
Seattle Children's Hospital
Seattle, Washington, United States
Start Date
September 28, 2022
Primary Completion Date
October 31, 2025
Completion Date
November 30, 2025
Last Updated
January 26, 2026
89
ACTUAL participants
Observational only: Serology and flow cytometry for ALL cohort participants
OTHER
Observational only: Infection rates
OTHER
Lead Sponsor
Children's Hospital of Philadelphia
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions